Efficacy and safety of dulaglutide monotherapy compared with glimepiride in Chinese patients with type 2 diabetes: Post‐hoc analyses of a randomized, double‐blind, phase III study

Aims/Introduction To investigate the efficacy/safety of dulaglutide once‐weekly monotherapy versus glimepiride in Chinese patients with type 2 diabetes. Materials and Methods This was a post‐hoc analysis of a Chinese randomized, double‐blind, non‐inferiority, phase III study. Patients (n = 572) with...

Full description

Saved in:
Bibliographic Details
Published in:Journal of diabetes investigation 2020-01, Vol.11 (1), p.142-150
Main Authors: Shi, Li Xin, Liu, Xiao Min, Shi, Yong Quan, Li, Quan Min, Ma, Jian Hua, Li, Yan Bing, Du, Li Ying, Wang, Feng, Chen, Lu Lu
Format: Article
Language:English
Subjects:
Aged
Antidiabetics
Asian People - statistics & numerical data
Biomarkers - analysis
Blood Glucose - analysis
Body mass index
Body Weight
Chinese
Diabetes
Diabetes mellitus (non-insulin dependent)
Diabetes Mellitus, Type 2 - drug therapy
Diabetes Mellitus, Type 2 - pathology
Diarrhea
Distension
Double-Blind Method
Double-blind studies
Drug dosages
Dulaglutide
Female
Follow-Up Studies
Glucagon-Like Peptides - analogs & derivatives
Glucagon-Like Peptides - therapeutic use
Glucose
Glycated Hemoglobin - analysis
Hemoglobin
Humans
Hypoglycemia
Hypoglycemic Agents - therapeutic use
Immunoglobulin Fc Fragments - therapeutic use
Insulin
International organizations
Male
Middle Aged
Nausea
Original
Patients
Peptides
Prognosis
Recombinant Fusion Proteins - therapeutic use
Standard deviation
Sulfonylurea Compounds - therapeutic use
Type 2 diabetes mellitus
Vomiting
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aims/Introduction To investigate the efficacy/safety of dulaglutide once‐weekly monotherapy versus glimepiride in Chinese patients with type 2 diabetes. Materials and Methods This was a post‐hoc analysis of a Chinese randomized, double‐blind, non‐inferiority, phase III study. Patients (n = 572) with inadequate glycemic control received dulaglutide 1.5 mg (n = 189) or 0.75 mg (n = 194) once‐weekly or glimepiride (1–3 mg/day; n = 189) for 26 weeks. The primary objective of the study was to investigate the non‐inferiority of dulaglutide 1.5 mg versus glimepiride by the change from baseline to week 26 in glycated hemoglobin (non‐inferiority margin 0.4%). Results Dulaglutide 1.5 mg and 0.75 mg were non‐inferior (P 
ISSN:2040-1116
2040-1124
DOI:10.1111/jdi.13075